<SEC-DOCUMENT>0001213900-22-082228.txt : 20221222
<SEC-HEADER>0001213900-22-082228.hdr.sgml : 20221222
<ACCEPTANCE-DATETIME>20221222164027
ACCESSION NUMBER:		0001213900-22-082228
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20221222
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221222
DATE AS OF CHANGE:		20221222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Citius Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001506251
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				273425913
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38174
		FILM NUMBER:		221482433

	BUSINESS ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016
		BUSINESS PHONE:		(908) 967-6676

	MAIL ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trail One, Inc.
		DATE OF NAME CHANGE:	20110314

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrailOne, Inc.
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea170685-8k_citius.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:CTXR="http://citiuspharma.com/20221222">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_035_CTXR_citiuspharma.com_20221222 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20221222_20221222 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DEntityCentralIndexKey_0001506251 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:EntityCentralIndexKey">0001506251</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ctxr-20221222.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-12-22to2022-12-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506251</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-22</xbrli:startDate>
        <xbrli:endDate>2022-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">UNITED STATES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES AND EXCHANGE COMMISSION</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Washington, D.C. 20549</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>FORM <span id="xdx_90A_edei--DocumentType_c20221222__20221222_zLeB5GkhQVU6"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b></b></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CURRENT REPORT</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Section 13 or 15(d) of</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">the Securities Exchange Act of 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported)
<span style="text-decoration: underline"><span id="xdx_90B_edei--DocumentPeriodEndDate_c20221222__20221222_zPUZNaT6t0M3"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December 22, 2022</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_905_edei--EntityRegistrantName_c20221222__20221222_zpZe49Elhhvd"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:EntityRegistrantName">Citius Pharmaceuticals, Inc.</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-decoration: underline"><span id="xdx_90C_edei--EntityIncorporationStateCountryCode_c20221222__20221222_z2jSEiJ3PWwk"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of incorporation)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--EntityFileNumber_c20221222__20221222_zprSElAJHVLc"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:EntityFileNumber">001-38174</ix:nonNumeric></span></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--EntityTaxIdentificationNumber_c20221222__20221222_zxd2VnmlQi85"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:EntityTaxIdentificationNumber">27-3425913</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer Identification
No.)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; width: 49%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_edei--EntityAddressAddressLine1_c20221222__20221222_zcbZFDSJddlk"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:EntityAddressAddressLine1">11 Commerce Drive</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressAddressLine2_c20221222__20221222_zSB1ojCq9Ouc"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:EntityAddressAddressLine2">1st Floor</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressCityOrTown_c20221222__20221222_zy60HmOaLQKc"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:EntityAddressCityOrTown">Cranford</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressStateOrProvince_c20221222__20221222_zP1kfrr1ERd"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:EntityAddressStateOrProvince">NJ</ix:nonNumeric></span></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 49%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_edei--EntityAddressPostalZipCode_c20221222__20221222_zVRAFtSNN8d1"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:EntityAddressPostalZipCode">07016</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Address of principal executive offices)</span></td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Zip Code)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&#8217;s telephone number, including area code
<span style="text-decoration: underline">(<span id="xdx_900_edei--CityAreaCode_c20221222__20221222_zNq9c3g9Qw34"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:CityAreaCode">908</ix:nonNumeric></span>) <span id="xdx_901_edei--LocalPhoneNumber_c20221222__20221222_zM1BfjGCiRpa"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:LocalPhoneNumber">967-6677</ix:nonNumeric></span> </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0.2in; margin-bottom: 0pt; text-align: left">Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--WrittenCommunications_c20221222__20221222_zOddkDhtAimh"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--SolicitingMaterial_c20221222__20221222_zbPtmvF32W65"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--PreCommencementTenderOffer_c20221222__20221222_zByU609pel75"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--PreCommencementIssuerTenderOffer_c20221222__20221222_zs9CbZ2NDsV"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each class</span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol(s)</span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--Security12bTitle_c20221222__20221222_zh8hP5BKP4cg"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:Security12bTitle">Common stock, $0.001 par value</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--TradingSymbol_c20221222__20221222_zqQh5IZxP5Lb"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:TradingSymbol">CTXR</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <span id="xdx_903_edei--SecurityExchangeName_c20221222__20221222_zMo2V8zOh2Xh"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">Emerging growth company <span id="xdx_90C_edei--EntityEmergingGrowthCompany_c20221222__20221222_z5LkNAGqxWm1"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><b>Item
2.02 Results of Operations and Financial Condition.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-indent: -58.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">On December 22, 2022, we issued a press release
announcing our results of operations for the full year of fiscal 2022. A copy of the press release is furnished as Exhibit 99.1 to this
report and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; background-color: white">The information in this
Item 2.02 (including Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of
1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such
a filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9.01. Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.5in; text-align: left">(d)</td><td style="text-align: justify">Exhibits</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; width: 9%"><span style="font-family: Times New Roman, Times, Serif">Exhibit&#160;No.</span></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 90%"><span style="font-family: Times New Roman, Times, Serif">Description</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">99.1</span></td>
    <td>&#160;</td>
    <td><a href="ea170685ex99-1_citius.htm"><span style="font-family: Times New Roman, Times, Serif">Press release, dated December 22, 2022.</span></a></td></tr>

<tr style="vertical-align: top; text-align: justify">
<td style="width: 9%; text-align: left">104</td>
    <td style="width: 1%">&#160;</td><td style="text-align: justify; width: 90%">Cover Page Interactive Data File (embedded within the Inline
XBRL document).</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -1.5in">&#160;</p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURE</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding-right: -9pt">&#160;</td>
    <td colspan="2" style="padding-right: -9pt"><span style="font-family: Times New Roman, Times, Serif"><b>CITIUS PHARMACEUTICALS, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 35%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">Date: <span style="text-decoration: underline">December 22, 2022</span></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">/s/ Leonard Mazur</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">Leonard Mazur</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">Chairman and Chief Executive Officer</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">2</p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2WUw36sG3korIIiSi1yXHWNIdmd2sPqm/bFWi4cIw3Dn3ChGKDa11jQyXZZHDCZu2Vg6hwAoZzRX9R7bdpeB3gTdtHSvjhvMHZuQZ9MwsSuZXbwyvnbZYppDIiewFsUynCSz2Iuj9jEylSzROqxqUKeHI1LJGp/g9JpzUiww176HqjGw1GR8XxaP9ARknEg7UqSfx3UKeZyIIhwnEhunR9jUP66iBVY2N77Ij+lfwBQ4aSTc= -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea170685ex99-1_citius.htm
<DESCRIPTION>PRESS RELEASE, DATED DECEMBER 22, 2022
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Citius Pharmaceuticals, Inc. Reports Fiscal
Full Year 2022 Financial Results and Provides Business Update</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">$41.7 million in cash and cash equivalents
as of September 30, 2022; extends runway through December 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Mino-Lok&reg; Phase 3 trial closer to completion
with 169 patients recruited, 72 failure events and 17 patients in active treatment or pending data review</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">I/ONTAK BLA accepted for filing by the FDA; updated
PDUFA target action date is July 28, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Halo-Lido Phase 2b trial progressed; data readout
expected 2H 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Multiple value-driving catalysts anticipated in
2023, including a potential drug approval and two trial completions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CRANFORD, N.J.</B>, December 22, 2022 -- Citius Pharmaceuticals,
Inc. (&ldquo;Citius&rdquo; or the &ldquo;Company&rdquo;) (Nasdaq: CTXR), <FONT STYLE="font-size: 10pt">a late-stage biopharmaceutical company
dedicated to the development and commercialization of first-in-class critical care products </FONT>today reported business and financial
results for the fiscal full year ended September 30, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Fiscal Full Year 2022 Business Highlights and Subsequent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Completed
Pivotal Phase 3 trial of I/ONTAK (E7777) and submitted biologics license application (BLA) to the U.S. Food and Drug Administration (FDA);</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FDA
confirmed Prescription Drug User Fee Act (PDUFA) target action date of July 28, 2023;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Advanced Mino-Lok<SUP>&reg;</SUP> Phase 3 trial:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">o</TD><TD STYLE="text-align: justify">Expanded trial to additional sites in India for an anticipated
total of 35 clinical trial locations globally,</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">o</TD><TD STYLE="text-align: justify">Enrolled 169 patients to date, exceeding recruitment goal
of 144 patients,</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">o</TD><TD STYLE="text-align: left">Observed 72 of 92 required catheter failure events, with
17 patients in active treatment or pending study completion data review (which may contribute additional failure events);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Initiated
Phase 2b trial of Halo-Lido for the treatment of hemorrhoids in April 2022; patient enrollment ongoing with data readout expected 2H
2023;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Initiated
clinical collaboration with the University of Pittsburgh to evaluate regulatory T-cell (T-reg) depletion with I/ONTAK (E7777) in combination
with pembrolizumab in recurrent or metastatic solid cancer tumors in a Phase 1 investigator-initiated trial, with first patient enrolled
in November 2022; and,</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Approved
for $3.6 million in non-dilutive capital through the New Jersey Economic Development Program to support ongoing research and development
efforts.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Financial Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
and cash equivalents of $41.7 million as of September 30, 2022;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">R&amp;D
expenses were $17.7 million for the full year ended September 30, 2022, compared to $12.2 million for the full year ended September 30,
2021;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">G&amp;A
expenses were $11.8 million for the full year ended September 30, 2022, compared to $9.8 million for the full year ended September 30,
2021;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock-based
compensation expense was $3.9 million for the full year ended September 30, 2022, compared to $1.5 million for the full year ended September
30, 2021; and,</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
loss was $33.6 million, or ($0.23) per share for the full year ended September 30, 2022 compared to a net loss of $23.1 million, or ($0.23)
per share for the full year ended September 30, 2021.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;In 2022, we focused on execution across our key development programs:
I/ONTAK, Mino-Lok and Halo-Lido. These efforts, combined with a prudent use of funds, enabled us to meaningfully advance our pipeline.
We believe we have sufficient runway through December 2023 to realize additional value-creating milestones, including a potential FDA
approval and two anticipated trial completions in the coming calendar year,&rdquo; stated Leonard Mazur, Chairman and CEO of Citius.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Our Phase 3 Mino-Lok trial is now significantly closer to completion.
While we expected to achieve 92 catheter failure events with 144 patients by the end of 2022, the trial&rsquo;s observed catheter failure
event rate has proven to be lower than anticipated. Consequently, we must continue recruiting patients. By successfully re-engaging with
our U.S. trial sites as they recovered from the impact of Covid, we were able to drive patient recruitment. We have now exceeded our targeted
enrollment and have achieved 72 of the required catheter failure events, with additional patients under review. To augment our recruitment
efforts and continue the positive momentum in enrollment, we expanded the Mino-Lok trial to include sites in India. Once all new trial
sites are fully activated, we will have nearly doubled our clinical site footprint. With these additional sites helping to drive incremental
enrollment, we anticipate that the 92-event threshold required to complete the trial is achievable in the coming months,&rdquo; added
Mazur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;During the year, we also completed a Phase 3 trial and submitted
a BLA for I/ONTAK, an oncology asset we in-licensed just over a year ago. Upon further discussion with the FDA, the PDUFA target date
has been set for July 28, 2023. We remain committed to establishing a robust commercial infrastructure to support I/ONTAK&rsquo;s successful
product launch, if approved. In the second half of 2022, we also extended our support for a Phase 1 investigator-initiated study of I/ONTAK
in combination with pembrolizumab (Keytruda<SUP>&reg;<FONT STYLE="font-size: 10pt">1</FONT></SUP>) to treat patients with recurrent
or metastatic solid tumors. This study has begun recruiting patients and is the second investigator-initiated trial to explore I/ONTAK&rsquo;s
potential as a combination therapy in much larger immuno-oncology markets. We continue to believe I/ONTAK&rsquo;s value extends beyond
a potential initial indication in persistent or recurrent cutaneous T-cell lymphoma. Earlier in the year, we announced our intention to
spin off I/ONTAK. Given broader market conditions, we continue to evaluate opportunities to further unlock this asset&rsquo;s value,&rdquo;
continued Mazur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;In addition to advancing our Phase 3 trials, we initiated a
Phase 2b trial for Halo-Lido, our prescription strength topical formulation for hemorrhoids. The trial began enrolling patients with symptomatic
Grade II or III hemorrhoids in the second quarter of 2022. Recent recruitment has accelerated and we expect complete trial data available
in the second half of 2023,&rdquo; added Mazur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>1</SUP></TD><TD STYLE="text-align: left">KEYTRUDA&reg; is a registered trademark of Merck Sharp &amp;
Dohme Corp., a subsidiary of Merck &amp; Co., Inc., Kenilworth, NJ, USA</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;As financial stewards, we continuously evaluate the optimal
capital structure for the company. We believe our anticipated catalysts, along with a healthy cash position, provide us with several strategic
and financial options with which to continue advancing our pipeline. This may include the previously announced potential spinoff of I/ONTAK
into a standalone oncology company, pending market conditions, and other standalone financing alternatives available to us. We are encouraged
by the multiple value-driving catalysts anticipated in calendar 2023, including a potential drug approval and two trial completions, and
look forward to extending our positive momentum in the months ahead,&rdquo; concluded Mazur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>Full Year 2022 Financial
Results:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of September 30, 2022, the Company had $41.7 million in cash and
cash equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of September 30, 2022, the Company had 146,211,130 common shares
outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company estimates that its available cash resources will be sufficient
to fund its operations through December 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Research and Development (R&amp;D) Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">R&amp;D expenses were $17.7 million for the full year ended September
30, 2022, compared to $12.2 million for the full year ended September 30, 2021. The increase of $5.5 million is primarily associated with
the completion of the I/ONTAK (E7777) Phase 3 trial and the preparation and submission of the related Biologics License Application to
the FDA, incremental Mino-Lok Phase 3 trial costs related to the addition of a global clinical research organization, Biorasi, and the
opening of international sites in India, as well as costs associated with the initiation of the Halo-Lido Phase 2 study. The increase
was offset primarily by a one-time $5 million license fee paid to Novellus in the year ended September 30, 2021, which did not recur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect that research and development expenses will continue to increase
in fiscal 2023 as we continue to focus on the anticipated commercialization of E7777, our Phase 3 trial for Mino-Lok, our Phase 2b trial
for Halo-Lido, and accelerate our research and development efforts related to Mino-Wrap and ARDS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General and Administrative (G&amp;A) Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">G&amp;A expenses were $11.8 million for the full year ended September
30, 2022, compared to $9.8 million for the full year ended September 30, 2021. The increase was primarily due to additional compensation
costs for new employees and investor relations expenses. General and administrative expenses consist primarily of compensation costs,
consulting fees for our financing activities and corporate development services, and investor relations expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Stock-based Compensation Expense</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the full year ended September 30, 2022, stock-based compensation
expense was $3.9 million as compared to $1.5 million for the prior year. The increase reflects expenses related to new grants made by
Citius and the NoveCite stock option plan. In fiscal year 2022, we granted options to our new employees and additional options to other
employees, directors, and consultants. Stock-based compensation expense includes options granted to directors, employees, and consultants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At September 30, 2022, unrecognized total compensation cost related
to unvested options for Citius common stock of $5.3 million is expected to be recognized over a weighted average period of 1.9 years and
unrecognized total compensation cost related to unvested options for NoveCite common stock of $0.2 million is expected to be recognized
over a weighted average period of 1.5 years</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Net loss</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net loss was $33.6 million, or ($0.23) per share for the year ended
September 30, 2022, compared to a net loss of $23.1 million, or ($0.23) per share for the year ended September 30, 2021. The increase
in net loss is primarily due to the $5.4 million increase in our research and development expenses, a $1.9 million increase in general
and administrative expenses, and a $2.4 million increase in stock-based compensation expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Citius Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Citius is a late-stage biopharmaceutical company dedicated to the development
and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique
prescription products, and stem cell therapies. The Company&rsquo;s diversified pipeline includes two late-stage product candidates, Mino-Lok&reg;,
an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections, which is currently enrolling patients
in a Phase 3 Pivotal superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy for an initial indication in CTCL, for which
a BLA is under review by the FDA. Mino-Lok&reg; was granted Fast Track designation by the FDA. I/ONTAK has received orphan drug designation
by the FDA for the treatment of CTCL and PTCL. In the first half of 2022, Citius initiated a Phase 2b trial for Halo-Lido, a topical formulation
for the relief of hemorrhoids. For more information, please visit www.citiuspharma.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Safe Harbor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release may contain &ldquo;forward-looking statements&rdquo;
within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements
are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact
that they use words such as &ldquo;will,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo; &ldquo;should,&rdquo;
and &ldquo;may&rdquo; and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management&rsquo;s
current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial
condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: our ability
to successfully undertake and complete clinical trials and the results from those trials for our product candidates; risks relating to
the results of research and development activities, including those from existing and new pipeline assets; uncertainties relating to preclinical
and clinical testing; the early stage of products under development; our need for substantial additional funds; our dependence on third-party
suppliers; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates
to impact the quality of life of our target patient populations; our ability to commercialize our products if approved by the FDA; market
and other conditions; our ability to attract, integrate, and retain key personnel; risks related to our growth strategy; patent and intellectual
property matters; our ability to attract, integrate, and retain key personnel; our ability to obtain, perform under and maintain financing
and strategic agreements and relationships; our ability to identify, acquire, close and integrate product candidates and companies successfully
and on a timely basis; our ability to procure cGMP commercial-scale supply; government regulation; competition; as well as other risks
described in our SEC filings. These risks have been and may be further impacted by Covid-19. Accordingly, these forward-looking statements
do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements.
Risks regarding our business are described in detail in our Securities and Exchange Commission (&ldquo;SEC&rdquo;) filings which are available
on the SEC&rsquo;s website at www.sec.gov, including in our Annual Report on Form 10-K for the year ended September 30, 2022, filed with
the SEC on December 22, 2022 and updated by our subsequent filings with the Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions
or circumstances on which any such statement is based, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Relations for Citius Pharmaceuticals:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investor Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ilanit Allen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ir@citiuspharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">908-967-6677 x113</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Media Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">STiR-communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Greg Salsburg</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Greg@STiR-communications.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">-- Financial Tables Follow &ndash;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>CITIUS PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SEPTEMBER 30, 2022 AND 2021</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">ASSETS</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Current Assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">41,711,690</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">70,072,946</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Prepaid expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,852,580</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,741,404</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Current Assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">44,564,270</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">72,814,350</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Property and equipment, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,100</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,023</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Operating lease right-of-use asset, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">646,074</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">822,828</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Other Assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,062</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,062</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">In-process research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">59,400,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">59,400,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Goodwill</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,346,796</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,346,796</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Other Assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">68,784,858</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">68,784,858</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total Assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">113,999,302</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">142,429,059</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Current Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,165,378</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,277,095</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,405,394</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">621,960</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accrued compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,762,251</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,906,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Operating lease liability</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">196,989</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">177,237</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font-weight: bold; text-align: left">Total Current Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,530,012</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,982,292</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Deferred tax liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,561,800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,985,800</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Operating lease liability &ndash; non current</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">481,245</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">678,234</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,573,057</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,646,326</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Commitments and Contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Stockholders&rsquo; Equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Common stock - $0.001 par value; 400,000,000 shares authorized; 146,211,130 and 145,979,429 shares issued and outstanding at September 30, 2022 and 2021, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">146,211</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">145,979</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">232,368,121</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">228,084,195</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(129,688,467</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(96,047,821</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font-weight: bold; text-align: left">Total Citius Pharmaceuticals, Inc. Stockholders&rsquo; Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">102,825,865</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">132,182,353</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Non-controlling interest</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">600,380</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">600,380</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">103,426,245</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">132,782,733</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total Liabilities and Equity</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">113,999,302</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">142,429,059</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CITIUS PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED SEPTEMBER 30, 2022 AND 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">Revenues</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Operating Expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; width: 76%; text-align: left">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">17,655,482</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">12,240,503</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,754,609</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,836,412</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Stock-based compensation &ndash; general and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,905,954</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,454,979</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Operating Expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">33,316,045</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">23,531,894</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Operating Loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(33,316,045</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(23,531,894</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Other Income (Expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">251,399</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">261,825</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Gain on forgiveness of note payable - Paycheck Protection Program and accrued interest</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">166,557</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Other income</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">59,917</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Interest expense</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(10,839</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Other&nbsp;Income, Net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">251,399</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">477,460</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Loss before Income Taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(33,064,646</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23,054,434</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Income tax expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">576,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net Loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(33,640,646</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23,054,434</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Deemed dividend on warrant extension</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,450,876</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Net Loss Applicable to Common Stockholders</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(33,640,646</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(24,505,310</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Net Loss Per Share Applicable to Common Stockholders - Basic and Diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.23</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.23</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Weighted Average Common Shares Outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">146,082,399</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">108,599,080</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CITIUS PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED SEPTEMBER 30, 2022 AND 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Cash Flows From Operating Activities:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(33,640,646</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(23,054,434</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,905,954</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,454,979</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Issuance of common stock for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">378,204</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">68,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Amortization of operating lease right-of-use asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">176,754</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">163,376</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,923</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,492</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Deferred income tax expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">576,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Gain from forgiveness of notes payable &ndash; paycheck protection program and accrued interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(166,557</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(111,176</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,619,167</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in">Deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,031</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(111,717</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(579,140</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">783,434</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">457,920</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Accrued compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(143,749</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">251,081</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Accrued interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(87,996</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Operating lease liability</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(177,237</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(158,999</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net Cash Used In Operating Activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(28,361,256</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(24,250,414</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash Flows From Investing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Purchase of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,938</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Purchase of in-process research and development</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(40,000,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net Cash Used In Investing Activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(40,006,938</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Cash Flows From Financing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Principal paid on notes payable &ndash; related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(172,970</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Proceeds from sale of NoveCite, Inc. common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Proceeds from common stock warrant exercises</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,130,134</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Proceeds from common stock option exercises</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82,634</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Net proceeds from private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,450,410</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net proceeds from registered direct offerings</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">70,979,842</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net Cash Provided By Financing Activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">120,470,550</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net Change in Cash and Cash Equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(28,361,256</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,213,198</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash and Cash Equivalents &ndash; Beginning of Year</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">70,072,946</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">13,859,748</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Cash and Cash Equivalents &ndash; End of Year</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">41,711,690</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">70,072,946</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">7</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  M 24# 2(  A$! Q$!_\0
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M UEXF\4Z"MW%<Q7%H=8TFQ%U:%[NW\RVBEE3-_9]_P""O'_!,K]J77M+\)?
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MZSHHT.SM?!^LZQ!I/B#2+FUBU-O%>F2:I9VAG>PTZ:]$=C^2'[)GQEN/CO\
M"H_%K3="N;";P]KNG>"/BG8VFF7\/A32O%^KZ?>ZMI]C;WL!%HF@^.=,TC6-
M6T#2'O8M3L%TG7M'VW$?A^VU[5?](3_@GOX<\(>%OV*?V;-.\"6VIV?AF_\
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MPJ@VN]?ZXG[5G_)KO[27_9 _C%_ZKSQ%7^;+_P &>/\ REF\1_\ 9HOQB_\
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M]=6?C[X7^'+H_$K1=-FT^QAG\;Z3<Z)XM^&82WEM;SQ/K=A$)I/TT_X)._\
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M2:NW:[V/AG1O^#B;_@C!K?A$^-(/V[_AO9:8EJ]U-INL^%/BMHWBZ(11I)+
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,:5.HVOM3FG=IM__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>ctxr-20221222.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /aIps7xRiXhun8uMb3AsOaaDKcPtypV1CYkxvG96HTkqbyspoZIzQSXaNlfG4XYF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:CTXR="http://citiuspharma.com/20221222" elementFormDefault="qualified" targetNamespace="http://citiuspharma.com/20221222">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://citiuspharma.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="ctxr-20221222_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ctxr-20221222_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>ctxr-20221222_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>ctxr-20221222_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://citiuspharma.com/role/Cover" xlink:href="ctxr-20221222.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://citiuspharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139672716683072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Dec. 22, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 22,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Citius Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001506251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3425913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11 Commerce Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">1st Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cranford<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">967-6677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CTXR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>ea170685-8k_citius_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ctxr-20221222.xsd" xlink:type="simple"/>
    <context id="From2022-12-22to2022-12-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506251</identifier>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-12-22to2022-12-22">0001506251</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-12-22to2022-12-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-12-22to2022-12-22">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-12-22to2022-12-22">2022-12-22</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-12-22to2022-12-22">Citius Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-12-22to2022-12-22">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-12-22to2022-12-22">001-38174</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-12-22to2022-12-22">27-3425913</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-12-22to2022-12-22">11 Commerce Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-12-22to2022-12-22">1st Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-12-22to2022-12-22">Cranford</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-12-22to2022-12-22">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-12-22to2022-12-22">07016</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-12-22to2022-12-22">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-12-22to2022-12-22">967-6677</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-12-22to2022-12-22">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-12-22to2022-12-22">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-12-22to2022-12-22">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-12-22to2022-12-22">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-12-22to2022-12-22">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-12-22to2022-12-22">CTXR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-12-22to2022-12-22">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-12-22to2022-12-22">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M-,#)U&5E837\*B'.CJ?J6>BA;T'*G?##0]C-/HR="+L5X25A[(*P@+'_AOM
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MPNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    "  +A995!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M  N%EE5<!XT2[@   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    (  N%EE697)PC$ 8  )PG   3
M  "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ "X6655W6
M<+-7!   &1$  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    (  N%EE6?H!OPL0(  .(,   -
M  "  9H,  !X;"]S='EL97,N>&UL4$L! A0#%     @ "X6659>*NQS
M$P(   L              ( !=@\  %]R96QS+RYR96QS4$L! A0#%     @
M"X665:K$(A8S 0  (@(   \              ( !7Q   'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    (  N%EE4D'INBK0   /@!   :              "
M ;\1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (  N%
MEE5ED'F2&0$  ,\#   3              "  :02  !;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@     )  D /@(  .X3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea170685-8k_citius.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://citiuspharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ea170685-8k_citius.htm">ea170685-8k_citius.htm</File>
    <File>ctxr-20221222.xsd</File>
    <File>ctxr-20221222_lab.xml</File>
    <File>ctxr-20221222_pre.xml</File>
    <File>ea170685ex99-1_citius.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ea170685-8k_citius.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "ea170685-8k_citius.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ctxr-20221222_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ctxr-20221222_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ctxr-20221222.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "CTXR",
   "nsuri": "http://citiuspharma.com/20221222",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea170685-8k_citius.htm",
      "contextRef": "From2022-12-22to2022-12-22",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://citiuspharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea170685-8k_citius.htm",
      "contextRef": "From2022-12-22to2022-12-22",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001213900-22-082228-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-22-082228-xbrl.zip
M4$L#!!0    (  N%EE7QCTZP4 ,  ,4,   1    8W1X<BTR,#(R,3(R,BYX
M<V2U5MMRVC 0?6YG^@^JWV5C:))"()D,F:1,R:609$A?.L(6H$%(1I*!].LK
MR39W*":MGZ35.6=WI5W)U<O9B(()%I)P5G-\M^  S (>$M:O.<]M>-6N-QH.
MN+SX]!'HK_H90G!#, TKX)H'L,%Z_!S<HQ&N@%O,L$"*BW/P@FAL+/R&4"Q
MG8\BBA76"XFG"CAQ_3,$(#Q ]P6SD(OG5F.N.U JDA7/FTZG+N,3-.5B*-V
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M9(*(V*94VWUMGNR\OA0T #A[*(&B41[O?Z.<?Q1R*<:4:"EH4MSJAY[P>XM
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M@I&YW'0#X?..QFI%UC6$%;B<\3OZ$@&OU^*'X4 ,TQ=W'";AAC^ #YGCLB%
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M!M2<W%/.$_]PN;&]0X-9<#HYSS=ZG+6%,TPMA  /@^_N='@'/L!S!,Z*LW>
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MAHS1E$_&1SC_W1W3L8&Y#SB::]P#QCXDY""$^88*^!GGK&GZ;)\4P_?3-$/
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M")\,^: -Z"S^"09&&Q\!L1VXKF+' ^X;G@_/F\R#AY##@TD 9!, E4@FKJP
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MS.5<9C+BJI#O"@XO3-R($$>"1WC,=NZ9!TQ&P/$!_.#0IZ7>XZ'WX53PO*-
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M,C(R7VQA8BYX;6Q02P$"% ,4    "  +A9956%/<UED'  #=5P  %0
M        @ &P#@  8W1X<BTR,#(R,3(R,E]P<F4N>&UL4$L! A0#%     @
M"X665>*6H\_'$@  Q7(  !8              ( !/!8  &5A,3<P-C@U+3AK
M7V-I=&EU<RYH=&U02P$"% ,4    "  +A995+_I5!HPH  !U= $ &0
M        @ $W*0  96$Q-S V.#5E>#DY+3%?8VET:75S+FAT;5!+!08
..!0 % % !  #Z40     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
